Alkermes plc. price to book ratio ALKS

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026: 4.0×
10-year median: 3.7×
Against its 10-year history: 60th; percentile: 0 is its lowest day, 100 its highest
10-year range: 1.9× to 8.7×
Peer median: 10.6×

Alkermes plc.'s price to book ratio is 4.0× as of Oct 23, 2026.

That is above its ten-year median of 3.7×, close to the middle of its last ten years.

Over that time it ranged from 1.9× in Mar 2020 to 8.7× in Feb 2018.

The median for 10 large drugmakers of a similar size is 10.6×.

Price to book ratio over time

median 3.7×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	4.0×	2.5×	5.2×
2025	2.7×	2.7×	4.0×
2024	3.7×	3.2×	4.2×
2023	3.4×	2.9×	5.5×
2022	4.1×	3.4×	4.8×
2021	3.4×	2.8×	4.7×
2020	2.9×	1.9×	3.2×
2019	3.0×	2.6×	5.0×
2018	3.8×	3.8×	8.7×
2017	7.1×	6.2×	7.8×
2016	7.0×	3.5×	7.8×
2015	8.7×	6.1×	8.7×
2014	6.3×	4.3×	7.1×
2013	5.5×	3.0×	5.5×
2012	2.8×	2.3×	3.1×
2011	2.5×	2.0×	2.5×

Against its peers

Companies in Drug Manufacturers - General nearest Alkermes plc.'s size, closest first, today.

Company	Price to book ratio
ALKSAlkermes plc.	4.0×
AMRXAmneal Pharmaceuticals	197×
TGTXTG Therapeutics	13.7×
LGNDLigand Pharmaceuticals	6.3×
KNSAKiniksa Pharmaceuticals International	9.2×
PTGXProtagonist Therapeutics	10.6×
CORTCorcept Therapeutics	13.2×
BMRNBiomarin Pharmaceutical	1.7×
INDVIndivior Pharmaceuticals	n/m
ARQTArcutis Biotherapeutics	17.8×
JAZZJazz Pharmaceuticals	2.9×
Peer median	10.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Alkermes plc.

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.